Wednesday, July 8, 2026

pharma · Prurigo Nodularis · Uremic Pruritus · TRVI

Trevi Therapeutics

Trevi Therapeutics clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

195 Church Street, 16th Floor, New Haven, CT 06510, US HQ
2011 Founded
45 Employees
Public company Type
TRVI · NYSE Ticker
Company details
Status
Public
HQ
195 Church Street, 16th Floor, New Haven, CT 06510, US
Founded
2011
Employees
45
Programs
11
Drugs
8
Patents
7
Intelligence · Clinical Programs

Trevi Therapeutics projects

3 ClinicalTrials.gov programs sponsored by Trevi Therapeutics.

Trevi Therapeutics has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. NAL ER

    Trevi Therapeutics

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    3 trials
  2. NAL ER

    Trevi Therapeutics

    Refractory Chronic Cough

    phase 2 small molecule completed

    1 trial
  3. NAL03-202

    Trevi Therapeutics

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Trevi Therapeutics have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.